{"name":"Yungjin Pharm. Co., Ltd.","slug":"yungjin-pharm-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Placebo(for Limaprost)","genericName":"Placebo(for Limaprost)","slug":"placebo-for-limaprost","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Placebo(for Limaprost)","genericName":"Placebo(for Limaprost)","slug":"placebo-for-limaprost","phase":"marketed","mechanism":"Placebo is an inert substance with no active pharmacological mechanism.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxQblQ2eEttMko4Zk1MM0JDdjNXTURkeXRzLTdfLUVxVy1BQmZqZlNkbXd2cVViSDhiX2dybXE0UldoSHdEbjNTa2pwNF9xeWdFMWlSbzlZUEd6RGJ1SHM2OVVWUEpOeG1nbG9vdFlmalp1YzZNd29uT2R6eTZnZkJSbkJ3bmc0Zi1SdEE5OVA5TGlCc2VmSjM4bHV1enJFUFpFY2RsdmJ0dkJxVFJELXcyMDN1bUNaOU1KSHp2cjJKUEwySWxLYWZSWnM0WWxMZDVzSTdOOU15X3BTSUVNVFpEc2FYU1VfQVQ3RjhUcVpPUkprLU1haGkzN291M3JKMTNKNXloU1lZemtFaTh2R1J0VlNTZ0J0U25EQU91QTVsUGc?oc=5","date":"2026-04-07","type":"trial","source":"Business Upturn","summary":"Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight - Business Upturn","headline":"Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxQQ1RoLWM1Skk4Y2xOUUo1eDJkNFJhZWRZV2N0eEZmV2hfci1uS2tvVjRiNTV1TUVrWGVBMXZzc2J0dnpQS0xma0dKZ0lUUThZRzd6ZTJZZHUzVF85SE5VcGlrdG5iWUVpRHZrUEdrYkJGZURZQ2IwRl9TOHZwLVdVQ0NXc2R3dnRxUDdIcllNaC14RjBRZEg3MmQ0aHlhNllSbkVaSC12Vld5eU9ZX2NnNnhJdlRJamhiaXNZMHFMNmdkcE1rMlVzRkxRaUo5enhJbUtvTFBJTzN1WkxtUC03elZnUWllTlQ1QnE3YkNVNjd6WlZiSnZLWnIwSWRPdnpnYTAwUUJrbUlndy1hSlZlTGJ4ZEZtRnBIMVRMMFpR?oc=5","date":"2026-03-30","type":"trial","source":"Barchart.com","summary":"Chronic Obstructive Pulmonary Disease Clinical Trial Pipeline Appears Robust With 65+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com","headline":"Chronic Obstructive Pulmonary Disease Clinical Trial Pipeline Appears Robust With 65+ Key Pharma Companies Actively Work","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxOVE83cG41VGdaa2U0WnpzYUpxVDlBLUtCa05DaTlhOUVQQWtXaFRMbTlXTEFlbnNybGhiSWVOT01XZ25BN2YzRjhKdm83YVFUY3ZldjAyLVJQY1lwVXExSDl3VkNBSVY0SDI3MGxUcXpwajZOMjdoWDNkS3FLTDZWb050UC1LQXpJTjRCZ0dpZS0wQjNFcmVtN2k2enhHQldtNEZrMmItaVFrMXhQTGJBcWRoVFRDNHpYUklWOFk0UEZmeHl5MnZDUjQ5aWVDLWItQWNHb0FZZmszZFNrS2xSWGRXeXEyWGJzR0p4Z29EMUZkaUNfZlZRVG81bDVMS01yYWllakR1WmtBU3UzeHc?oc=5","date":"2025-10-21","type":"regulatory","source":"PR Newswire","summary":"Emphysema Market Analysis Reveals Promising Growth Opportunities and Trends During the Forecast Period (2025-2034) | DelveInsight - PR Newswire","headline":"Emphysema Market Analysis Reveals Promising Growth Opportunities and Trends During the Forecast Period (2025-2034) | Del","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxQSDRlcTFteFU3MEkzSnNQdTRXV2RZMTZ4RGk1ZTkyblltZTI1SDBBWjkzUnhNVmpTRkM1dDk0YnA3VWlJcVZnQ0pMMllPQ3RkOENmYkRxYldTcVpLQkh6ZEYxWUVUSlNXWVZsS3ZnazZRR3BzSllPNUFvM1hTRXdudjZacm91QkFGWkluWlZOdThaLUpXU2QwVS1JV0dzdFZndVJHVHdEMVJ6UkpxVUUwUFdXRENxLUtOTjdSMGdqWHdrNUkwVTBPdjlQazB5Z3hjTktIbXROcmt0Uk5XNThfVnRYVF9KQlY2bVhCUW5sRGdXUVdiTE9pdGFVRy0xVVliNjNMZFRfblpfVkdsSENjQ2RLdThzczQ?oc=5","date":"2025-03-04","type":"regulatory","source":"PR Newswire UK","summary":"Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance | DelveInsight - PR Newswire UK","headline":"Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1OMl9TUzhuc1djcW1DUVlTQ19FUFpSa3NLT1BHeEctcTBLWkNNaFE5NGlGZGVCamhWU0hIZTlERmdUSmhMMjlLUlMyQnEtekJGbDJmMmszQVBGWGdpSWFPR2xnZFBTRjAzQW1scndn?oc=5","date":"2023-09-12","type":"deal","source":"KED Global","summary":"Wellmarker Bio signs worth of $528 mn tech transfer deal - KED Global","headline":"Wellmarker Bio signs worth of $528 mn tech transfer deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE83ckZ1dFozLWlkenBXTmd1MG9PaUtyLXAwYjlEcC1wS240QlNUMHU2YXhENERpeUswcTY4M0NmQlE1M1NFWTZZRS15eUVRTWZyNjV4ZEJlaHhfVHMyRURRalBhS09JUEpLMG90aWhR?oc=5","date":"2023-09-06","type":"regulatory","source":"KED Global","summary":"Yungjin Pharm's new drug candidate gets Fast Track from FDA - KED Global","headline":"Yungjin Pharm's new drug candidate gets Fast Track from FDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPYXFwZ3BwV3JmVkVSakFUUnpaQVhFcFdseXlEY3RIUUdTMFVlaC1HR0RuQkhYSDYzQW1UcGU3R2pHOGZOUHhKUjdtQ3FPQzcwY1VVLWJPOUFjZUdkS3FVSExlRUJmdlNaZHJTNDB1bktlMHVwQ04xdnoxQTI5WWg2MnJ1UmZ5NGUxMnVqbS13dzdKdUZ5RlZNS2xoWVVRWmpPRTBpbUZLMF9SVVFXYWRJeXlZYkRqd2NBXzV0OE9wU1p4YXM1enVtbl9zRElqQjhpX0swUldGcy0xTlRXbU5lbG9HeXhreEg3elllYW1Hc2RSY3pTU3ZWWEVIYWE1NV90Uld3X05vbXQ?oc=5","date":"2022-07-26","type":"pipeline","source":"PR Newswire","summary":"New Therapeutics Options in Rheumatoid Arthritis Pipeline as 120+ Key Companies are Working on Drug Profiles | DelveInsight - PR Newswire","headline":"New Therapeutics Options in Rheumatoid Arthritis Pipeline as 120+ Key Companies are Working on Drug Profiles | DelveInsi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQOERYc0JMX2QtNWZpalhISmxCUGJ4NEZBM0RqQklmV1BmZVF4Z0hzMEhpMlNWN0JNVVBFZjdvRktsYlp5OURoUnZwdmVURXYwWWNMelV4LWc4MmhOaEMzWjFNY3ZOaHgxcG9LSlo3R0YxQlFycjZ1UDVrdllJM1ZJeU9JS1NGdGQ3TERhS0hEbTdRQkc0VXFXaHJ5NEViNnhHTXpPSGhuTVNXVzNuME5UdDlIWFM?oc=5","date":"2021-11-11","type":"pipeline","source":"Korea JoongAng Daily","summary":"Korean pharmaceutical companies build business at CPhI - Korea JoongAng Daily","headline":"Korean pharmaceutical companies build business at CPhI","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}